169590-41-4

Basic information

• Product Name: Deracoxib
• Synonyms: Benzenesulfonamide, 4-3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl-;4-(3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide;Deracoxib [usan];Deramaxx;Sc 46;Sc 59046;Unii-vx29jb5xwv;4-[5-(3-Fluoro-4-Methoxyphenyl)-3-(difluoroMethyl)-1H-pyrazol-1-yl]benzenesulfonaMide
• CAS NO: 169590-41-4
• Molecular Formula: C₁₇H₁₄F₃N₃O₃S
• Molecular Weight: 397.38
• EINECS: 1308068-626-2
• Mol File: 169590-41-4.mol
• Article Data: 25

Chemical Properties

• Melting Point: 159-161°
• Boiling Point: 575.5°C at 760 mmHg
• Flash Point: 301.9°C
• Appearance: /
• Density: 1.48
• Vapor Pressure: 3E-13mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: 2-8°C
• Solubility: Acetonitrile (Slightly), DMSO (Slightly)
• PKA: 9.69±0.10(Predicted)
• CAS DataBase Reference: Deracoxib(CAS DataBase Reference)
• NIST Chemistry Reference: Deracoxib(169590-41-4)
• EPA Substance Registry System: Deracoxib(169590-41-4)

Safety Data

• Hazardous Substances Data: 169590-41-4(Hazardous Substances Data)

Usage

Description

Deracoxib, a member of the pyrazole class, is a non-steroidal anti-inflammatory drug (NSAID) belonging to the coxib class. It is a selective cyclooxygenase-2 (COX-2) inhibitor characterized by its 1H-pyrazole structure, which is substituted at positions 1, 3, and 5 by 4-sulfamoylphenyl, difluoromethyl, and 3-fluoro-4-methoxyphenyl groups, respectively. Deracoxib is primarily used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs.

Uses

Used in Veterinary Medicine:
Deracoxib is used as an anti-inflammatory agent for the treatment of osteoarthritis in dogs. It acts as a selective COX-2 inhibitor, helping to control pain and inflammation without causing significant gastrointestinal side effects at low doses.
Used in Pain Management:
In addition to its use in treating osteoarthritis, Deracoxib is also utilized for managing pain in dogs. Its selective COX-2 inhibition allows for effective pain relief with a lower risk of gastrointestinal complications compared to some other NSAIDs.
Used in Inflammation Control:
Deracoxib is employed as an inflammation control agent, helping to reduce the inflammation associated with various conditions in dogs. Its selective COX-2 inhibition makes it a suitable choice for controlling inflammation while minimizing potential side effects.

Veterinary Drugs and Treatments

Deracoxib is indicated for the treatment of post-operative pain (higher dose, 7 day maximum), and for the treatment of pain and inflammation associated with osteoarthritis (lower dose, ongoing dosing) in dogs. Like piroxicam, deracoxib is of interest in adjunctive treatment of transitional cell carcinoma of the bladder; investigations into this use are ongoing.

InChI:InChI=1/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)

Upstream product

• 17852-52-7 4-hydrazinobenzene-1-sulfonamide hydrochloride 
• 321-28-8 1-fluoro-2-methoxybenzene 
• 170570-77-1 4,4-difluoro-1-(3-fluoro-4-methoxyohenyl)-butane-1,3-dione 
• 288-13-1 NH-pyrazole 
• 454-31-9 ethyl difluoroacetate 
• 455-91-4 1-(3-fluoro-4-methoxyphenyl)ethanone 

Relevant articles and documents

Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib

We have identified a new reactivity of copper/diamine catalysis for the reductive ring-cleavage of isoxazoles to yield fluoroalkylated enaminones. This protocol has the advantage of using commercially available reagents, ease of setting up, broad tolerance of functionality, and is regiospecific and free of defluorination and reduction of reducible functional groups. The utility was demonstrated by a one-step, regioselective synthesis of fluoroalkylated pyrazole-based drugs such as celecoxib, deracoxib, and mavacoxib.

COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR

The present invention provides a combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor for the treatment or prevention of pain or nociception.

Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor

This invention relates to the use of a tocolytic agent or agents in combination with selective cyclooxygenase-2 inhibitors of Formula (II) or a pharmaceutically-acceptable salt or derivative thereof for preparing a medicament for maintaining circulation through fetal ductus arteriosus during treatment or prevention of preterm labor in a subject in need of such treatment or prevention.